MetaCap

PDS Biotechnology (PDSB) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Unicycive Therapeutics (UNCY) over the past year, gaining 3.0% versus a loss of 38.0%. Over five years, UNCY leads with a -88.5% price change compared with -92.5% for PDSB. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $95.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PDSB+2.97%UNCY-37.96%
+121%+19%-83%
Nov 21, 20251 yearNov 20, 2026
PDSB-92.26%UNCY-87.07%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PDSB versus UNCY key metrics
MetricPDSBUNCY
Share price$0.7774$3.35
Market cap$95.39M$97.77M
1-day change-3.70%-5.10%
YTD return+0.96%-41.94%
1-year return+2.97%-37.96%
5-year return-92.46%-88.53%
Forward P/E—4.86
EPS (TTM)$-0.54$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.50M$-26.55M
52-week high$1.79$8.74
52-week low$0.195$3.33
Distance from 52-week high-56.57%-61.67%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+478.85%+685.07%
Average volume25.64M963.80K
Shares outstanding122.70M29.18M
Employees2121
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed UNCY by 40.9 percentage points over the past year.

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

PDSB vs UNCY FAQ

Which is bigger, PDS Biotechnology or Unicycive Therapeutics?

Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $95.39M for PDS Biotechnology (PDSB).

Which stock has performed better over the past year, PDSB or UNCY?

PDSB returned +2.97% over the past 12 months, compared with -37.96% for UNCY (price return, excluding dividends). Past performance does not predict future results.

Are PDS Biotechnology and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons